Prostate Articles & Analysis

With Halloween in the dust and an honourable mention to Intelex’s very own Brandyn Berry for the stylin’ Michael Jackson costume he moon-walked through the office last Friday, today marks the start of the Movember fundraising campaign, both globally and here at Intelex. For those who haven’t heard of Movember, it’s a campaign that raises funds and awareness for prostate ...

By Intelex Technologies Inc.

Filtricine is pleased to announce that researchers leading a Filtricine-sponsored prostate cancer clinical study at Stanford University School of Medicine presented results from the first 10 participants at the 2021 Annual Prostate Cancer Foundation Scientific Retreat. The poster presented featured early results from “A Feasibility Study to Deplete Non-Essential Amino Acids in Patients ...

By Filtricine, Inc.

This is my first year with Intelex and what better way to get to know my fellow coworkers than by growing moustaches together? Yes, that’s right: the Intelex family participated in this year’s Movember. Ah, how my upper lip does miss its fuzzy warmth (sadly I had to say goodbye to it on December 1st). In addition to Intelexians raising $2,635 throughout the month of November to ...

By Intelex Technologies Inc.

Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management. RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced Artificial Intelligence (AI) and computer vision solutions, today announces a new tool for prostate MRI analysis. The tool performs segmentation ...

By RSIP Vision

Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate. In the UK, prostate cancer is the most common cancer in men and in Wales, more than 2,500 men each year are diagnosed with prostate cancer. Radiotherapy is included as part of primary treatment in approximately 30% of ...

By MediWales

In honor of November being prostate cancer awareness month, today’s post is dedicated to discussing prostate exams and how medical professionals can help make them as comfortable as possible. This is in an effort to help promote as many men as possible to have their prostates checked to reduce the incidence of prostate cancer or to identify it in the earlier stages. Before we dive right ...

By HR® Pharmaceuticals, Inc.

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique ...

By Cancer Targeted Technology

Basel, March 23, 2022 — Novartis announced today that the US Food and Drug Administration (FDA) approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castrationresistant prostate cancer (PSMA-positive ...

By Advanced Accelerator Applications SA

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the upcoming oral presentation of key results from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer, at the upcoming ASCO 2022 Genitourinary Cancers Symposium (ASCO GU). The conference will be held in-person in ...

By Blue Earth Diagnostics

C4 Imaging LLC is pleased to announce an additional US Food and Drug Administration 510(k) clearance for its Sirius MRI Marker, a novel positive-signal MRI Marker that is used during the treatment of prostate cancer with brachytherapy. This additional 510(k) clears Sirius MRI Markers to be sterilized with ethylene oxide. Previously only gamma sterilization was available; the addition of ethylene ...

By C4 Imaging LLC

Pittsburgh, PA – (May 9, 2022) – Lipella Pharmaceuticals, Inc. is announcing the Radiation Cystitis Patient Registry, an on-line patient registry program for people who are affected by pelvic radiation exposure, including survivors of pelvic cancers, such as prostate, uterine, cervical and colon cancer. ...

By Lipella Pharmaceuticals Inc.

Ryan Rhodes, new CEO of EDAP USA was featured in MDDI this week. Rhodes hales from Intuitive Surgical where he helped build the DaVinci Robot brand. He compares HIFU to the early days of robotic surgery: “The HIFU market is still in its infancy, and Rhodes said it reminds him of his early days at Intuitive Surgical, when the Irvine, CA-based robotics company was focused on prostate cancer, ...

By EDAP TMS

Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer (mCRPC) versus standard of care alone. Many patients with mCRPC live with reduced physical functioning as ...

By Advanced Accelerator Applications SA

The TURP Primer is especially geared towards all urologists and their assistants who are interested in learning how to perform TURP or who are already performing TURP and would like to deepen their understanding of the physical and technical fundamentals. This primer is available in German language and provides an overview of the most important TURP developments of the past 20 years to today. In ...

By FARCO-PHARMA GmbH

We are pleased to offer congratulations to Professor Jurgen Fütterer and his team at Radboud University Medical Centre in the Netherlands, for having successfully secured €3.8 million from the Dutch National Health Care Institute and ZonMw towards the ENFORCE trial, a fully funded Randomised Controled Trial for Focal Therapy which incorporates the NanoKnife System as a treatment option ...

By AngioDynamics, Inc.

The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131 has been included in ABS’s highly respected consensus guidelines. Because Cesium-131 seeds were not available as a treatment until 2004, long-term outcomes ...

By Theragenics

Cancer Targeted Technology (CTT) receives milestone payment for development of diagnostic PET imaging agent for prostate cancer. Seattle, Washington, June 2021. Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology company, received a milestone payment from Advanced Accelerator Applications International S.A. (AAA), a Novartis company, triggered by the upcoming clinical ...

By Cancer Targeted Technology

Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, today announced the release of a new review paper titled "Immunohistochemistry in Prostate Pathology" that illustrates the significant impact immunohistochemistry (IHC) can have on diagnostic prostate pathology. The paper is co-authored by two leading global experts in prostate pathology: Glen Kristiansen, M.D., ...

By Agilent Technologies, Inc.

Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation. Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs ...

By Nanostics Inc.

Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...

By ProUroCare Medical Inc.